AR090151A1 - Compuestos inhibidores de raf - Google Patents
Compuestos inhibidores de rafInfo
- Publication number
- AR090151A1 AR090151A1 ARP130100576A ARP130100576A AR090151A1 AR 090151 A1 AR090151 A1 AR 090151A1 AR P130100576 A ARP130100576 A AR P130100576A AR P130100576 A ARP130100576 A AR P130100576A AR 090151 A1 AR090151 A1 AR 090151A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- pyrido
- compound
- inhibiting compounds
- dimethylbutyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title 1
- HHCBMISMPSAZBF-UHFFFAOYSA-N LY3009120 Chemical group CC1=NC2=NC(NC)=NC=C2C=C1C1=CC(NC(=O)NCCC(C)(C)C)=C(F)C=C1C HHCBMISMPSAZBF-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607702P | 2012-03-07 | 2012-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090151A1 true AR090151A1 (es) | 2014-10-22 |
Family
ID=47884613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100576A AR090151A1 (es) | 2012-03-07 | 2013-02-26 | Compuestos inhibidores de raf |
Country Status (39)
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| JP2019517549A (ja) * | 2016-06-10 | 2019-06-24 | ノバルティス アーゲー | Ｃ−ｒａｆ阻害薬の治療的使用 |
| EP3878850A1 (en) | 2016-12-22 | 2021-09-15 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| JP2020518660A (ja) * | 2017-04-28 | 2020-06-25 | クォーツ セラピューティクス，インコーポレイティド | Ｒａｆ分解性結合体化合物 |
| PH12020550786A1 (en) | 2017-12-21 | 2021-04-12 | Boehringer Ingelheim Int | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
| JP7161849B2 (ja) * | 2018-01-24 | 2022-10-27 | 株式会社クラレ | 第一級アミンの製造方法 |
| SG11202007287XA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of mastocytosis |
| BR112020015581A2 (pt) | 2018-01-31 | 2021-02-02 | Deciphera Pharmaceuticals, Llc | terapia de combinação para o tratamento de tumores estromais gastrointestinais |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| CN118453608A (zh) | 2018-12-28 | 2024-08-09 | 德西费拉制药有限责任公司 | 用于治疗癌症的csf1r抑制剂 |
| SMT202400003T1 (it) | 2019-02-06 | 2024-03-13 | Lilly Co Eli | Derivati di 1-((2-(2,2,2-trifluoroetossi)piridin-4-il)metil)urea come potenziatori di kcnq |
| TWI756636B (zh) * | 2019-02-18 | 2022-03-01 | 美商建南德克公司 | 嘧啶并嘧啶化合物及使用方法 |
| CN114072148A (zh) * | 2019-05-03 | 2022-02-18 | 金耐特生物制药公司 | Raf激酶的抑制剂 |
| KR20220008873A (ko) | 2019-05-10 | 2022-01-21 | 데시페라 파마슈티칼스, 엘엘씨. | 페닐아미노피리미딘 아미드 자가포식 억제제 및 이의 사용 방법 |
| BR112021022576A2 (pt) | 2019-05-10 | 2022-01-25 | Deciphera Pharmaceuticals Llc | Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de uso dos mesmos |
| JP7626722B2 (ja) | 2019-06-17 | 2025-02-04 | デシフェラ・ファーマシューティカルズ，エルエルシー | アミノピリミジンアミドオートファジー阻害剤およびその使用方法 |
| KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| CN114845711B (zh) | 2019-10-24 | 2024-10-01 | 皮埃尔法布雷医药公司 | Raf激酶的抑制剂 |
| PL4084779T3 (pl) | 2019-12-30 | 2025-02-24 | Deciphera Pharmaceuticals, Llc | Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika |
| CN119950433A (zh) | 2019-12-30 | 2025-05-09 | 德西费拉制药有限责任公司 | 非晶型激酶抑制剂制剂及其使用方法 |
| EP4157837B1 (en) | 2020-06-02 | 2024-12-18 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US11407737B2 (en) | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CN116507627A (zh) | 2020-11-02 | 2023-07-28 | 勃林格殷格翰国际有限公司 | 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物 |
| JP2023549540A (ja) | 2020-11-18 | 2023-11-27 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法 |
| CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
| MX2023012515A (es) | 2021-04-23 | 2023-12-15 | Kinnate Biopharma Inc | Tratamiento del cancer con un inhibidor de raf. |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| TW202337432A (zh) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| US20250313553A1 (en) | 2021-12-01 | 2025-10-09 | Boehringer Ingelheim Int'l GmbH Corp. | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| EP4441053A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US20250129096A1 (en) | 2021-12-01 | 2025-04-24 | Boehringer Ingelheim Int'l GmbH Corp. | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099620A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
| IL312905A (en) | 2021-12-01 | 2024-07-01 | Boehringer Ingelheim Int | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023108108A1 (en) | 2021-12-09 | 2023-06-15 | Deciphera Pharmaceuticals, Llc | Raf kinase inhibitors and methods of use thereof |
| JP2024546107A (ja) | 2021-12-09 | 2024-12-17 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｒａｆキナーゼ阻害剤及びその使用方法 |
| WO2023118250A1 (en) | 2021-12-23 | 2023-06-29 | Boehringer Ingelheim International Gmbh | 8-aza quinazolines as brain-penetrant sos1-inhibitors |
| WO2023173017A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| CA3266173A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING |
| CA3267008A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING |
| WO2024089008A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| TW202511268A (zh) | 2023-05-30 | 2025-03-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之螺環狀2-胺基-3-氰基噻吩及衍生物 |
| GB2631397A (en) | 2023-06-28 | 2025-01-08 | Sevenless Therapeutics Ltd | New treatments for pain |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| GB2633813A (en) | 2023-09-21 | 2025-03-26 | Sevenless Therapeutics Ltd | New treatments for pain |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025083426A1 (en) | 2023-10-20 | 2025-04-24 | Sevenless Therapeutics Limited | New treatments for pain |
| WO2025122952A1 (en) | 2023-12-08 | 2025-06-12 | Deciphera Pharmaceuticals, Llc | Formulations of vimseltinib |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025146548A1 (en) | 2024-01-04 | 2025-07-10 | Sevenless Therapeutics Limited | Sos1 inhibitors useful to treat pain and cancer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250313560A1 (en) | 2024-04-03 | 2025-10-09 | Boehringer Ingelheim International Gmbh | Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003033472A1 (en) * | 2001-10-17 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors |
| AU2003280599A1 (en) * | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| WO2011100319A1 (en) * | 2010-02-09 | 2011-08-18 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors |
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
-
2013
- 2013-02-26 AR ARP130100576A patent/AR090151A1/es unknown
- 2013-02-27 TW TW102107122A patent/TW201348233A/zh unknown
- 2013-03-05 US US14/383,799 patent/US9334267B2/en not_active Expired - Fee Related
- 2013-03-05 HR HRP20160654TT patent/HRP20160654T1/hr unknown
- 2013-03-05 BR BR112014018528A patent/BR112014018528A8/pt not_active IP Right Cessation
- 2013-03-05 IN IN1575MUN2014 patent/IN2014MN01575A/en unknown
- 2013-03-05 SI SI201330188A patent/SI2850082T1/sl unknown
- 2013-03-05 KR KR1020147024732A patent/KR20140129087A/ko not_active Abandoned
- 2013-03-05 MX MX2014010701A patent/MX2014010701A/es unknown
- 2013-03-05 HK HK15103082.6A patent/HK1202541A1/xx unknown
- 2013-03-05 MA MA37316A patent/MA37316B1/fr unknown
- 2013-03-05 CN CN201380012913.9A patent/CN104302646B/zh not_active Expired - Fee Related
- 2013-03-05 WO PCT/US2013/029098 patent/WO2013134252A1/en not_active Ceased
- 2013-03-05 SG SG11201404969YA patent/SG11201404969YA/en unknown
- 2013-03-05 PT PT137120051T patent/PT2850082T/pt unknown
- 2013-03-05 WO PCT/US2013/029084 patent/WO2013134243A1/en not_active Ceased
- 2013-03-05 ME MEP-2016-124A patent/ME02423B/me unknown
- 2013-03-05 PE PE2014001381A patent/PE20142338A1/es not_active Application Discontinuation
- 2013-03-05 ES ES13712005.1T patent/ES2584387T3/es active Active
- 2013-03-05 AU AU2013230146A patent/AU2013230146B2/en not_active Ceased
- 2013-03-05 LT LTEP13712005.1T patent/LT2850082T/lt unknown
- 2013-03-05 NZ NZ627454A patent/NZ627454A/en not_active IP Right Cessation
- 2013-03-05 EA EA201491456A patent/EA024824B1/ru not_active IP Right Cessation
- 2013-03-05 DK DK13712005.1T patent/DK2850082T3/en active
- 2013-03-05 HU HUE13712005A patent/HUE028095T2/en unknown
- 2013-03-05 RS RS20160416A patent/RS54840B1/sr unknown
- 2013-03-05 US US13/785,575 patent/US8741911B2/en not_active Expired - Fee Related
- 2013-03-05 AP AP2014007899A patent/AP2014007899A0/xx unknown
- 2013-03-05 JP JP2014561029A patent/JP2015509536A/ja not_active Ceased
- 2013-03-05 EP EP13712005.1A patent/EP2850082B1/en active Active
- 2013-03-05 CA CA2863673A patent/CA2863673A1/en not_active Abandoned
- 2013-05-03 UA UAA201409109A patent/UA112340C2/uk unknown
-
2014
- 2014-07-24 CO CO14161404A patent/CO7010837A2/es unknown
- 2014-08-11 IL IL234052A patent/IL234052A/en not_active IP Right Cessation
- 2014-08-12 CR CR20140378A patent/CR20140378A/es unknown
- 2014-08-21 CL CL2014002220A patent/CL2014002220A1/es unknown
- 2014-09-03 TN TNP2014000375A patent/TN2014000375A1/fr unknown
- 2014-09-04 DO DO2014000200A patent/DOP2014000200A/es unknown
- 2014-09-05 PH PH12014501986A patent/PH12014501986B1/en unknown
- 2014-09-05 EC ECIEPI201417584A patent/ECSP14017584A/es unknown
-
2016
- 2016-07-22 CY CY20161100719T patent/CY1117846T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090151A1 (es) | Compuestos inhibidores de raf | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| CL2013002177A1 (es) | Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos. | |
| AR096759A1 (es) | Formas sólidas de un inhibidor de quinasa macrocíclica | |
| IL244611B (en) | Compounds containing compressed pyrimidine/4,2,1-triazine two-ring systems as inhibitors of jak3 and/or btk kinase activity | |
| SG11201604519PA (en) | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof | |
| MY164705A (en) | Imidazo [4,5-c] quinolin - 2 - one compound and its use as pi3 kinase / mtor dual inhibitor | |
| MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
| PH12014500883A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| MX391724B (es) | Nuevos derivados de triazolo[4,5-d]pirimidina. | |
| DOP2011000260A (es) | Pirimidinas fusionadas | |
| GEP20186876B (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| CL2016000496A1 (es) | Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias. | |
| WO2014152996A8 (en) | Crystalline form of a beta-lactamase inhibitor | |
| UA115357C2 (uk) | Похідні піридин-4-ілу | |
| EA201892726A1 (ru) | Дейтерированный палбоциклиб | |
| CL2014001863A1 (es) | Sal fosfato de dihidropirrolo [1,2-c] imidazolilo, inhibidor de la aldosterona sintasa o aromatasa; forma cristalina a; sal nitrato; procedimiento para preparar una sal nitrato o fosfato cristalina; composicion farmaceutica; y su uso para el tratamiento del sindrome de cushing. | |
| PH12015502122A1 (en) | Sovaprevir polymorphs and methods of manufacturing thereof | |
| WO2014160177A3 (en) | Quinazoline inhibitors of pi3k | |
| PL3008063T3 (pl) | Pochodne 4-amino-6-(2,6-dichlorofenylo)-2-(fenyloamino)pirydo(2,3- d)pirymidyn-7(8h)-onu, ich synteza oraz zastosowania | |
| AR066550A1 (es) | Sales monoclorhidrato de un inhibidor de histona deacetilasa | |
| ES2672509T3 (es) | Forma polimórfica cristalina de acetato de ulipristal | |
| ZA201500129B (en) | Anti-tumoral compositions comprising the compound 1-6(6-{[6-94-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea | |
| TH155634A (th) | พิร์โรลิดีนซึ่งถูกแทนที่ซึ่งเป็นสารยับยั้งแฟคเตอร์ Xlaสำหรับการรักษาโรคลิ่มเลือดหลุดอุดหลอดเลือด |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |